RxSight (RXST) Cash & Current Investments (2020 - 2026)

RxSight (RXST) has 7 years of Cash & Current Investments data on file, last reported at $418.2 million in Q1 2026.

• Quarterly Cash & Current Investments fell 2.89% year-over-year to $418.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $418.2 million (down 2.89% YoY) and the FY2025 annual result came in at $436.3 million, up 83.91% from the prior year.
• Cash & Current Investments eased to $418.2 million in Q1 2026, from $436.3 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $442.0 million in Q2 2024 to a low of $143.8 million in Q1 2022.
• A 5-year average of $300.9 million and a median of $253.9 million in 2023 frame the typical range for Cash & Current Investments.
• The widest YoY moves for Cash & Current Investments: up 187.61% in 2022, down 32.11% in 2022.
• Tracing RXST's Cash & Current Investments over 5 years: stood at $199.8 million in 2022, then advanced by 22.49% to $244.7 million in 2023, then slipped by 3.05% to $237.2 million in 2024, then jumped by 83.91% to $436.3 million in 2025, then decreased by 4.14% to $418.2 million in 2026.
• The last three Cash & Current Investments figures came in at $418.2 million (Q1 2026), $436.3 million (Q4 2025), and $425.4 million (Q3 2025), per Business Quant data.